<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03877718</url>
  </required_header>
  <id_info>
    <org_study_id>CL02-204</org_study_id>
    <nct_id>NCT03877718</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain</brief_title>
  <official_title>A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain, With or Without Aura, and the Prevention of Migraine Associated Nausea and Vomiting.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charleston Laboratories, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charleston Laboratories, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine&#xD;
      Pain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Multicenter, Randomized, Double-Blind, Comparator-Controlled, Placebo-Controlled Study to&#xD;
      Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain, With&#xD;
      or Without Aura, and the Prevention of Migraine-Associated Nausea and Vomiting (MANV)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Actual">August 27, 2019</completion_date>
  <primary_completion_date type="Actual">August 27, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects who are pain-free 2 hours after taking investigational treatment</measure>
    <time_frame>2 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects who are nausea-free 2 hours after taking investigational treatment</measure>
    <time_frame>2 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with no vomiting 2 hours after taking the investigational treatment</measure>
    <time_frame>2 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">475</enrollment>
  <condition>Migraine</condition>
  <condition>Pain</condition>
  <condition>Nausea</condition>
  <condition>Vomiting</condition>
  <condition>Aura</condition>
  <arm_group>
    <arm_group_label>Arm 1: CL-H1T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maximum dosage within a 24-hour period: One capsule of CL-H1T (total dose: sumatriptan succinate 90mg/promethazine hydrochloride 18.75mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: CL-H1T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maximum dosage within a 24-hour period: One capsule of CL-H1T (total dose: sumatriptan succinate 90mg/promethazine HCl 37.5mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: Sumatriptan succinate 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maximum dose within a 24 hour period: One capsule of sumatriptan succinate 100mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4: Promethazine HCl 18.75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maximum dose within a 24 hour period: One capsule of promethazine HCl 18.75mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5: Promethazine HCl 37.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maximum dose within a 24 hour period: One capsule of promethazine HCl 37.5mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 6: Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maximum dose within a 24 hour period: One capsule of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm 1: CL-H1T</intervention_name>
    <description>One capsule of CL-H1T (total dose: sumatriptan succinate 90mg/promethazine HCl 18.75 mg)</description>
    <arm_group_label>Arm 1: CL-H1T</arm_group_label>
    <other_name>sumatriptan succinate 90mg/promethazine HCl 18.75mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm 2: CL-H1T</intervention_name>
    <description>One capsule of CL-H1T (total dose: sumatriptan succinate 90mg/promethazine HCl 37.5 mg)</description>
    <arm_group_label>Arm 2: CL-H1T</arm_group_label>
    <other_name>sumatriptan succinate 90mg/promethazine HCl 37.5mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm 3: Sumatriptan Succinate 100 mg capsule</intervention_name>
    <description>One capsule of sumatriptan succinate 100 mg</description>
    <arm_group_label>Arm 3: Sumatriptan succinate 100 mg</arm_group_label>
    <other_name>Sumatriptan succinate 100 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm 4: Promethazine HCl 18.75 mg</intervention_name>
    <description>One capsule of promethazine HCl 18.75 mg</description>
    <arm_group_label>Arm 4: Promethazine HCl 18.75 mg</arm_group_label>
    <other_name>Promethazine HCl 18.75</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm 5: Promethazine HCl 37.5 mg</intervention_name>
    <description>One capsule of promethazine HCl 37.5 mg</description>
    <arm_group_label>Arm 5: Promethazine HCl 37.5 mg</arm_group_label>
    <other_name>Promethazine HCl 37.5</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One capsule of placebo</description>
    <arm_group_label>Arm 6: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able to understand and willing to give written informed consent and authorize the&#xD;
             Health Insurance Portability and Accountability Act (HIPAA) prior to entering the&#xD;
             study.&#xD;
&#xD;
          2. Men and women with episodic migraine who meet the criteria of the International&#xD;
             Headache Society's Headache Classification Committee for migraine with or without&#xD;
             aura.&#xD;
&#xD;
          3. Between the ages of 18 and 75 years of age, inclusive.&#xD;
&#xD;
          4. A history of episodic migraine for at least 1 year.&#xD;
&#xD;
          5. Maximal frequency of 8 migraine attacks per month; minimum frequency of 2 migraine&#xD;
             attacks per month; at least 48 hours of headache-free time between migraine attacks.&#xD;
&#xD;
          6. Maximum total headache days of 14 per month.&#xD;
&#xD;
          7. History of migraine headache with nausea â‰¥ 50% of the time.&#xD;
&#xD;
          8. Able and willing to complete an electronic diary (eDiary) to record the details of a&#xD;
             migraine attack treated with investigational treatment.&#xD;
&#xD;
          9. Able to swallow a capsule whole.&#xD;
&#xD;
         10. Report headache on the Headache Pain Scale at Baseline before treatment.&#xD;
&#xD;
         11. Report the presence of nausea on the Nausea Scale at Baseline before treatment.&#xD;
&#xD;
         12. Women of childbearing potential (WOCBP) must practice an acceptable method of birth&#xD;
             control (acceptable methods of birth control in this study include: surgical&#xD;
             sterilization, intrauterine device, oral contraceptive, contraceptive patch,&#xD;
             long-acting injectable contraceptive, partner's vasectomy, or a double-barrier method&#xD;
             [condom or diaphragm with spermicide]). Use of intrauterine devices and hormonal&#xD;
             contraceptives must begin at least 8 weeks prior to Screening.&#xD;
&#xD;
         13. Willing and able to comply with the protocol requirements for the duration of the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A clinically significant or unstable medical or surgical condition that would preclude&#xD;
             safe and complete study participation. Such conditions may include cardiac,&#xD;
             respiratory, hepatic, renal or metabolic diseases, peripheral vascular disease, any&#xD;
             systemic disease, acute infection, or neurological disease (including Parkinson's&#xD;
             Disease or other condition associated with a movement disorder), current malignancy or&#xD;
             recent history (within 5 years) of malignancy (other than squamous cell or basal cell&#xD;
             carcinoma) or any medical condition that, in the opinion of the Investigator, makes&#xD;
             the subject unsuitable for participation in the study.&#xD;
&#xD;
          2. A positive saliva screen for alcohol or a positive urine drug screen for cocaine,&#xD;
             narcotics, benzodiazepines, opioids, tetrahydrocannabinol (THC), barbiturates,&#xD;
             amphetamines, or any prescription drugs unless such a positive result can be explained&#xD;
             by stated concomitant medications.&#xD;
&#xD;
          3. Regularly smoke cigarettes or use opiate analgesic drugs, benzodiazepines, ergot&#xD;
             containing drugs, alcohol, THC, or other drugs of abuse that, at the discretion of the&#xD;
             Investigator, may interfere with the evaluation of the endpoints in the trial.&#xD;
&#xD;
          4. Unstable use of prophylactic migraine medication (eg, change of dose or type of&#xD;
             medication) during the 30 days prior to Screening Visit.&#xD;
&#xD;
          5. Subjects using monoamine oxidase-A (MAO-A) inhibitors and who cannot be washed out.&#xD;
&#xD;
          6. Subjects using selective serotonin reuptake inhibitors (SSRIs), serotonin&#xD;
             norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, THC, or&#xD;
             systemic corticosteroids over the past month prior to the Screening Visit.&#xD;
&#xD;
          7. Daily use of antipsychotics at least 15 days prior to randomization.&#xD;
&#xD;
          8. Medication overuse:&#xD;
&#xD;
               1. Opioids for headache â‰¥ 10 days during the 90 days prior to Screening Visit;&#xD;
&#xD;
               2. Combination medications that contain an opioid and/or barbiturate (eg, FiorinalÂ®)&#xD;
                  â‰¥ 10 days during the 90 days prior to Screening Visit.&#xD;
&#xD;
               3. Nonsteroidal anti-inflammatory drugs (NSAIDs) or other simple medications Ëƒ 14&#xD;
                  days a month during the 90 days prior to Screening Visit.&#xD;
&#xD;
               4. Triptans or ergots â‰¥ 10 days a month during the 90 days prior to Screening Visit.&#xD;
&#xD;
          9. Use of mini prophylaxis for menstrual migraine.&#xD;
&#xD;
         10. History of allergic reaction or drug sensitivity to any triptans.&#xD;
&#xD;
         11. History of allergic reaction or drug sensitivity to promethazine.&#xD;
&#xD;
         12. History of allergic reaction or drug sensitivity to acetaminophen.&#xD;
&#xD;
         13. History of extrapyramidal reaction (eg, akathisia or dystonia) to neuroleptic&#xD;
             treatments.&#xD;
&#xD;
         14. Subjects who are pregnant (positive urine hCG: Human chorionic gonadotropin test at&#xD;
             Screening Visit) or breastfeeding.&#xD;
&#xD;
         15. Use of experimental or investigational treatments and/or participation in drug&#xD;
             clinical studies within the 6 months before the Screening Visit.&#xD;
&#xD;
         16. Subjects who are employees of the Sponsor.&#xD;
&#xD;
         17. Relatives of, or staff directly reporting to, the Investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernard P. Schachtel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Charleston Laboratories</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Suncoast Clinical Research, Inc.</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harmony Clinical Research, Inc.</name>
      <address>
        <city>North Miami Beach</city>
        <state>Florida</state>
        <zip>33162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mountain View Cl inical Research, Inc.</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 5, 2019</study_first_submitted>
  <study_first_submitted_qc>March 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2019</study_first_posted>
  <last_update_submitted>October 31, 2019</last_update_submitted>
  <last_update_submitted_qc>October 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Migraine Pain</keyword>
  <keyword>Acute Migraine Pain, With or Without Aura</keyword>
  <keyword>Prevention of Migraine Associated Nausea and Vomiting (MANV)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Promethazine</mesh_term>
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Sumatriptan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

